Valdés PT, Romeu CCR

Language: Spanish
References: 9
Page: 1-12
PDF size: 603.42 Kb.

ABSTRACT

Introduction: Docetaxel is a semi-synthetic drug with demonstrated antitumor activity approved for the treatment of patients with breast cancer, hormone- refractory prostate cancer and gastric cancer, locally advanced or metastatic. It is administered by slow intravenous infusion, so it is necessary to carry out a stability study in use to guarantee that the product is stable in these conditions.
Objective: Validate an analytical method to determine the stability in use of the injectable docetaxel-10 mg/mL.
Methods: The method was based on the separation of the active substance through an Apollo-C18 chromatographic column (5 μm) (250 x 4.6 mm), with ultraviolet detection at 232 nm. A mobile phase composed of a mixture of methanol: acetonitrile: water (44:26:30), with a flow rate of 1.5 mL/min, was used. The calibration curve was performed in the range of 0.125 mg/mL to 0.375 mg/mL.
Results: The method was linear, with a correlation coefficient equal to 1.0. Statistical evidence for intercept and slope was considered non-significant and significant, respectively. The coefficient of variation in the repeatability study was equal to 0.25% for the six replicates tested, while in the intermediate accuracy analyses the Fischer and Student's t tests were not significant. A recovery of 100.43% was obtained in the range of concentrations studied and the Cochran and Student's t tests were not significant. In the specificity study, no interference from additional peaks was observed near the retention time of the main product. The analytical method was linear, precise, accurate and specific in the range of concentrations studied.
Conclusions: The validated analytical method to determine the stability in use of the injectable docetaxel-10 mg/mL, turned out to be linear, precise, accurate and specific in the range of concentrations established between 0.125-0.375 mg/mL. The results allow to use the method for the realization of the stability study in use of the product in solutions of dextrose 5 % and sodium chloride 0.9 %.

REFERENCES

1. Tanay MA, Armes J, Ream E. The experience of chemotherapy-induced peripheralneuropathy in adult cancer patients: a qualitative thematic synthesis. Eur J Cancer Care. 2017;26(5). DOI: 10.1111/ecc.12443

2. Stoicescu EA, Burcea M, Iancu RC, Zivari M, Popa Cherecheanu A, Bujor IA, et al.Docetaxel for Breast Cancer Treatment-Side Effects on Ocular Surface, a SystematicReview. Processes. 2021;9(7):1086. DOI: 10.3390/pr9071086

3. Gallego-Yerga L, Posadas I, de la Torre C, Ruiz-Almansa J, Sansone F, Ortiz Mellet C.Docetaxel-Loaded Nanoparticles Assembled from β-Cyclodextrin/Calixarene GiantSurfactants: Physicochemical Properties and Cytotoxic Effect in Prostate Cancer andGlioblastoma Cells, Frontiers in Pharmacology. 2017;8:249. DOI: 10.3389/fphar.2017.0024

4. Colectivo de autores. Monografía “Docetaxel”, Handbook on Injectable Drugs.Wisconsin: American Society of Health-System Pharmacists, 20 Ed. 2018 vol. 18 p. 402-406.

5. The United States Pharmacopeial Convention. Farmacopea de los Estados Unidos. 42 ed.Estados Unidos de América NF-37. Rockville: Mack Printing; 2019.

6. Izquierdo A. “Determinación de Docetaxel, inyectable 80 mg/bbo, CIDEM, Técnica No.PT11009. La Habana: CIDEM; 2009.

7. Colectivo de autores. Validation of analytical procedures. Technical requirements for theregistration of pharmaceuticals for human use. Geneva: International Conference onHarmonization ICH-Q2A; 1995.

8. Centro para el Control Estatal de Medicamentos, Equipos y Dispositivos Médicos.Resolución No 40/2014. Anexo No. I de la Regulación No 37/2012, Buenas Prácticas paraLaboratorios de Control de Medicamentos. Validación de Métodos Analíticos. La Habana:CECMED; 2014.

9. Quattrocchi OA, Laba RF. Introducción a la HPLC en Aplicación y práctica. BuenosAires: Ed. Artes Gráficas Farro; 1992 p. 106-122, 284, 302-328.